Preclinical proof of concept for the first [18F]-Nanocyclix®TKI-PET radiotracer targeting activated EGFR positive lung tumors - Archive ouverte HAL Access content directly
Conference Poster Year :

Preclinical proof of concept for the first [18F]-Nanocyclix®TKI-PET radiotracer targeting activated EGFR positive lung tumors

, , , , , , , , , , (1) , (1) , , , ,
1
C Berthet
  • Function : Author
O Raguin
  • Function : Author
S Chalon
X Tizon
  • Function : Author
S Serrière
  • Function : Author
P Provent
  • Function : Author
M Hillairet de Boisferoni
  • Function : Author
G Serini
  • Function : Author
J Vercouillie
  • Function : Author
C Mothes
  • Function : Author
D Guilloteau
  • Function : Author
P Blom
  • Function : Author
J Hoflack
  • Function : Author
P. Genne
  • Function : Author
Not file

Dates and versions

hal-02386511 , version 1 (29-11-2019)

Identifiers

  • HAL Id : hal-02386511 , version 1

Cite

C Berthet, O Raguin, S Chalon, X Tizon, S Serrière, et al.. Preclinical proof of concept for the first [18F]-Nanocyclix®TKI-PET radiotracer targeting activated EGFR positive lung tumors. American Association for Cancer Research, Apr 2017, Washington, France. ⟨hal-02386511⟩
23 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More